Cadence Pharmaceuticals Inc.
) recently announced that it expects preliminary net revenue of
Ofirmev (acetaminophen) injection to be approximately $17.1
million for the fourth quarter. Thepreliminary revenue guidance
is above the earlier projection of approximately $15.9 million to
$16.4 million issued during the third quarter earnings release.
The remaining financial results for 2012 will soon be
Cadence expects net revenue estimate for Ofirmev to be in the
range of $94 million to $100 million approximately in 2013.
Ofirmev is Cadence Pharmaceuticals' proprietary intravenous
formulation of acetaminophen. It is indicated to manage
mild-to-moderate and moderate-to-severe pain with adjunctive
opioid analgesics as well as for the reduction of fever.
It was approved by the US FDA in Nov 2010 and subsequently
launched in the US in Jan 2011. The US Food and Drug
Administration (FDA) approval was based on data from clinical
trials in around 1,020 adults and 355 pediatric patients.
The exclusive rights to Ofirmev in the US and Canada were
acquired by Cadence from
) in 2006. The drug is marketed by Bristol-Myers as Perfalgan in
Europe and other parts of the world.
Cadence is working on increasing Ofirmev's access in various
hospitals. As of Sep 30, 2012, Ofirmev was ordered by nearly
3,500 unique accounts. Ofirmev customer base was increased by 10%
in the third quarter as compared to the second quarter of
Cadence carries a Zacks Rank #4 (Sell). Right now
) look more attractive with a Zacks Rank #1 (Strong Buy).
AGENUS INC (AGEN): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis
CADENCE PHARMA (CADX): Free Stock Analysis
TARGACEPT INC (TRGT): Free Stock Analysis
To read this article on Zacks.com click here.